CytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast Cancer

CytoDyn’s leronlimab will enter two new Phase 1 mTNBC trials starting in 2027.

What the company is saying

CytoDyn is announcing that leronlimab, its CCR5-targeting monoclonal antibody, will be tested in two new metastatic triple-negative breast cancer (mTNBC) regimens within the Quantum Leap Healthcare Collaborative’s PRE-I-SPY Phase 1-1b platform study. The company frames this as a significant opportunity to advance leronlimab’s role in combination immunotherapy, emphasizing the drug’s potential to modulate the tumor microenvironment and inform future treatment strategies. The announcement highlights the use of established partners and regimens: PRE5 will combine leronlimab with Merck's pembrolizumab and sacituzumab, while PRE7 will pair it with Akeso's penpulimab and standard chemotherapies. The company stresses the studies’ focus on safety, tolerability, and exploratory biomarker analysis, including ctDNA and PD-L1 expression. Jacob Lalezari, M.D., Head of Research and Translational Sciences at CytoDyn, and Paula Pohlmann, M.D., Ph.D., principal investigator from MD Anderson Cancer Center, are named as key scientific leads. The tone is optimistic, but all claims are forward-looking, with no efficacy or financial data presented. The company is supplying the drug but is not the trial sponsor.

What the data suggests

The announcement provides detailed clinical trial design information: both PRE5 and PRE7 are Phase 1 studies using a de-escalation design starting at 700mg leronlimab, with dose reductions based on a 21-day dose-limiting toxicity observation period. Each cohort will enroll six patients and may expand if no DLTs are observed. PRE5 targets first- or second-line mTNBC patients, while PRE7 focuses on second-line patients; both require a combined positive score (CPS) of less than 10. Enrollment for PRE5 is expected in Q1 2027, with PRE7 following in Q2 or Q3 2027. The sponsor is QLHC, not CytoDyn, and CytoDyn’s role is limited to drug provision. No patient data, efficacy results, or financial figures are disclosed. The evidence is limited to protocol and timeline specifics, with all clinical and commercial outcomes yet to be determined.

Analysis

The announcement is upbeat in tone, emphasizing the initiation of two new Phase 1-1b studies for leronlimab in metastatic triple-negative breast cancer. However, all key claims are forward-looking: enrollment for both studies will not begin until 2027, and no patient data, efficacy results, or even enrollment have occurred yet. The language highlights the 'potential' of leronlimab and the opportunity to 'explore preliminary signals,' but no realised clinical or financial milestones are disclosed. The only concrete facts are the planned study designs, dosing, and timelines. There is no mention of capital outlay or financial impact, and the company is only providing drug supply, not sponsoring the trials. The gap between narrative and evidence is moderate: the announcement frames the studies as significant progress, but in reality, they are at the preparatory stage with benefits several years away and no guarantee of success.

Risk flags

• ●There is substantial execution risk: neither study has begun enrollment, and timelines place first patient dosing at least several months in the future, with all results and downstream milestones contingent on successful completion of these early safety cohorts.
• ●The studies are Phase 1 and focused on safety and tolerability, so there is no guarantee of efficacy signals or progression to later-stage trials; failure to demonstrate safety or preliminary activity could halt development.
• ●CytoDyn is not the sponsor and has limited control over trial conduct, timelines, or protocol changes, which could delay or alter the program’s trajectory.
• ●No financial, operational, or R&D spending data is disclosed, leaving investors unable to assess CytoDyn’s ability to support ongoing development or withstand delays.
• ●The announcement is highly forward-looking, with all potential value dependent on future events and no realised clinical or commercial milestones to date.

Bottom line

CytoDyn is positioning leronlimab for evaluation in two new Phase 1 mTNBC studies within the PRE-I-SPY platform, but enrollment will not begin until 2027 and all outcomes remain speculative. The company is providing the drug, while Quantum Leap Healthcare Collaborative sponsors the trials, limiting CytoDyn’s operational control and financial exposure. The announcement is detailed on study design and timelines but contains no efficacy, enrollment, or financial data, and all clinical benefit is years away. Investors should recognize that this is a preparatory-stage update with no immediate catalysts or value inflection points. Progress will depend on timely enrollment, demonstration of safety, and any preliminary activity signals, none of which are guaranteed. The most important takeaway is that this is a long-lead, early-stage clinical development update with high uncertainty and no near-term impact on CytoDyn’s commercial or financial position.

Announcement summary

(OTCQB:CYDY) CytoDyn Inc. announced that leronlimab will be evaluated in two new metastatic triple-negative breast cancer (mTNBC) regimens within the Quantum Leap Healthcare Collaborative’s (QLHC) PRE-I-SPY Phase 1-1b platform study. The two studies, PRE5 and PRE7, will each assess leronlimab in distinct immunotherapy-based combinations that incorporate a PD-1 inhibitor. PRE5 will evaluate leronlimab with Merck's pembrolizumab and the antibody-drug conjugate sacituzumab, while PRE7 will evaluate leronlimab with Akeso's penpulimab and the chemotherapy agents gemcitabine and carboplatin. Both studies are designed to assess safety and tolerability in earlier-line metastatic treatment settings and to explore preliminary signals of clinical activity. Jacob Lalezari, M.D., Head of Research and Translational Sciences at CytoDyn, stated that these studies are an important opportunity to further investigate the potential of CCR5 inhibition as part of combination treatment strategies for mTNBC. The studies will incorporate exploratory biomarker assessments, including circulating tumor DNA (ctDNA) and PD-L1 expression, to generate early insights for future clinical development. Paula Pohlmann, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center, is the principal investigator for both studies. Both studies will primarily evaluate safety and tolerability, assess preliminary clinical activity, and include exploratory biomarkers such as ctDNA and PD-L1 expression measured by combined positive score (CPS). PRE5 will enroll patients receiving first- or second-line treatment, while PRE7 will focus on second-line treatment patients. Both studies will include patients with a CPS of less than 10. The study arms will use a de-escalation design starting at the highest dose of leronlimab (700mg) and will evaluate dose reductions based on a one-cycle, 21-day dose-limiting toxicity (DLT) observation period. Each cohort will include six patients and may expand if no DLTs are observed in the first cohort. QLHC is the sponsor of the PRE-I-SPY platform study, and CytoDyn is providing leronlimab for evaluation. Laura Esserman, M.D., Co-founder of QLHC and Principal Investigator of the I-SPY 2 platform, stated that the goal of PRE-I-SPY is to identify promising therapeutic combinations with acceptable safety profiles for potential evaluation in earlier-stage, high-risk breast cancer through the I-SPY 2.2 platform. Preparations for both studies are underway. Enrollment for PRE5 is expected to begin in the first quarter of calendar 2027, and enrollment for PRE7 is likely to begin in the second or third quarter of calendar 2027. Additional information and updates on both studies will be provided in future company communications.

Disagree with this article?